February 05, 2020 06:35 ET | Source: Meticulous Market Research Pvt. Ltd.
London, Feb. 05, 2020 (GLOBE NEWSWIRE) -- According to a new market research report Radiotherapy Marketby Product (Radiotherapy Devices, Software, Service), Procedure (EBRT, Brachytherapy, Systemic Radiotherapy), Technology (IMRT, SRT, VMAT, HDRBT, LDRBT, PDRBT), Application (Prostate, Breast) Global Forecasts to 2025, published by Meticulous Research, the radiotherapy market is expected to grow at a CAGR of 5.6% from 2019 to reach $10.15 billion by 2025.
DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5023
Cancer is among the major healthcare concerns for the healthcare systems across the world. While it is among one of the leading causes of deaths, the overall expenditure on cancer diagnostics and treatment is also one of the challenging issues for health systems across the world. As per the statistics, Cancer causes about 1 in every 6 deaths worldwide, which is more than AIDS, tuberculosis, and malaria combined. According to the WHO, cancer is the second leading cause of deaths globally. According to Global Cancer Observatory (GLOBOCAN), in 2012, about 14.1 million new cancer cases were diagnosed worldwide, which increased by ~28% to reach 18.1 million new cases in 2018 and claimed an estimated 9.6 million lives. Further, by 2040, the global cancer burden is expected to grow to 27.5 million new cancer cases and account for 16.3 million cancer deaths with simultaneous growth in aging population. The growing incidence and prevalence of cancer has led to greater demand for advanced therapies for cancer treatment. With advances in medical procedures such as radiotherapy, it is now possible to provide more accurate and targeted cancer treatment.
Radiotherapy is the type of cancer radiation treatment that utilizes beams of higher energy to kill cancer cells. Radiation kills cancer cells by directly affecting the DNA or by indirectly making free radicals that diffuse towards the DNA of damaged cells and destroys them. As cancer cells do not have the ability to repair themselves in the same way as normal cells, the radiation treatment leads to complete destruction of tumor cells. Since its initial adoption, radiation therapy has come a long way from treatment planning based on orthogonal radiographs with large margins around tumors. Advances in imaging modalities and radiation planning software have further led to three-dimensional conformal radiotherapy with accurate lesion detection and targeting.
Technological variations and advancements in radiotherapy, such as IMRT, IGRT, and 3-DCRT have provided the ability to precisely conform doses only to the tumor and haveminimized the need for fractionated treatments. Newer techniques, such as stereotactic body radiation therapy proved to be an effective radiotherapy technique with high radiation delivery and promising clinical outcomes. Further, proton and heavy ion therapy gained significant attraction as a breakthrough radiotherapy procedure as it reduces the radiation dose and the toxicities as compared to the traditional radiotherapy methods. In addition, researchers have also combined immunotherapy and radiotherapy to find the optimal radiation doses and balance the immunogenic effects caused due to radiation.
The global radiotherapy market studied in this report is segmented on the basis of procedure (external beam radiotherapy, internal beam radiotherapy), product (radiotherapy devices, radiotherapy consumables & accessories, software, and services), technology {external beam radiotherapy (IMRT, IGRT, SRT, 3D-CRT, and particle therapy) and internal beam radiotherapy [brachytherapy (HDR Brachytherapy, LDR Brachytherapy, IGBT, PDR Brachytherapy) and Systemic Radiation Therapy (Intravenous Radiotherapy and Oral Radiotherapy)]}, application (prostate, brain, breast, lung, head & neck, colorectal, cervical, others), end user (hospitals, independent radiotherapy centers, and cancer research institutes), and geography.
On the basis of procedure, the external beam radiotherapy segment commanded the largest share of the overall radiotherapy market in 2019. Higher installations of external beam radiotherapy equipment, majorly linear accelerators based teletherapy units, due to their technical features like precise radiation delivery, less damage to normal tissues even at high radiation doses, and continuous advances in existing products is supporting the largest share of this segment.
On the basis of product type, radiotherapy devices commanded the largest share of the overall radiotherapy market in 2019. Increasing technological advancements and growing focus of key players on the development of new devices are the major factors driving the growth of the radiotherapy devices market. On the basis of application, the breast cancer segment held the largest share of the overall radiotherapy market in 2019. The factors such as growing incidence of breast cancer and increasing volume of diagnostic procedures and treatment for the disease are supporting the largest share of this segment.
Have Any Query? Ask Our Experts:https://www.meticulousresearch.com/speak-to-analyst/cp_id=5023
On the basis of end user, hospitals commanded the largest share of the overall radiotherapy market in 2019; however, radiotherapy centers segment is estimated to grow at the fastest CAGR during the forecast period owing to increasing number of radiotherapy centers across the globe and government investments towards building radiotherapy facilities in developing regions.
Geographically, North America accounted for the largest share of the overall radiotherapy market in 2019, followed by Europe and Asia-Pacific region. However, Asia- Pacific region is expected to witness a rapid growth during the forecast period. The rapid growth of this market is mainly attributed to rising incidence and prevalence of cancer, rising awareness of various healthcare services and treatment options, rising number of middle-class population and their level of disposable income, increasing health insurance penetration, and growing aging population.
Some of the key players operating in the global radiotherapy market are Varian Medical Systems, Inc. (U.S.), Elekta AB (Sweden), Accuray Incorporated (U.S.), C. R. Bard, Inc. (U.S.), Mevion Medical Systems, Inc. (U.S.), Hitachi, Ltd. (Japan), ViewRay, Inc. (U.S.), Panacea Medical Technologies Pvt. Ltd. (India), Isoray, Inc. (U.S.), Optivus Proton Therapy, Inc. (U.S.), P-Cure, Ltd. (Israel), Provison Healthcare, LLC (U.S.), Ion Beam Applications S.A. (Belgium), and Theragenics Corporation (U.S.).
To gain more insights into the market with a detailed table of content and figures, click here:https://www.meticulousresearch.com/product/radiotherapy-market-5023/
Table of Content:
1. Introduction 1.1. Market Ecosystem 1.2. Currency and Limitations 1.2.1. Currency 1.2.2. Limitations 1.3. Key Stakeholders
2. Research Methodology 2.1. Secondary Research 2.1. Primary Research
3. Executive Summary
4. Market Insights 4.1. Introduction 4.2. Market Dynamics 4.2.1. Drivers 4.2.1.1. Growing Awareness About the Benefits of Radiotherapy for Cancer Treatment 4.2.1.2. Increasing Incidence & Prevalence of Cancer 4.2.1.3. Technological Advancements in the Field of Radiotherapy 4.2.2. Restraints 4.2.2.1. High Cost and Complexities Associated with Radiotherapy Procedures 4.2.2.2. Paucity of Skilled Healthcare Professionals 4.2.2.3. Lack of Advanced Infrastructure Facilities 4.2.3. Challenges 4.2.3.1. Difficulties in Visualizing Tumours during Radiotherapy Procedures 4.2.3.2. Risks due to Radiation Exposures 4.2.4. Opportunities 4.2.4.1. Significant Opportunities from Developing Economies 4.2.4.2. Growing Government Investment for Treatment of Cancer
5. Radiotherapy Market, by Procedure 5.1. Introduction 5.2. External Beam Radiotherapy 5.2.1. Linac Based Teletherapy 5.2.2. Proton Therapy 5.2.3. Cobalt-60 Based Teletherapy 5.3. Internal Beam Radiotherapy 5.3.1. Brachytherapy 5.3.2. Systemic Radiotherapy
6. Radiotherapy Market, by Product 6.1. Introduction 6.2. Radiotherapy Devices 6.2.1. External Beam Radiotherapy Systems 6.2.1.1. Conventional Linear Accelerators 6.2.1.2. Conventional Co-60 Teletherapy Units 6.2.1.3. Advanced Stereotactic Radiotherapy Systems 6.2.1.3.1. Gamma Knife 6.2.1.3.2. CyberKnife 6.2.1.3.3. TomoTherapy 6.2.1.4. Proton Therapy Systems 6.2.1.4.1. Cyclotron 6.2.1.4.2. Synchrotron 6.2.1.4.3. Synchrocyclotron 6.2.2. Internal Beam Radiotherapy Systems 6.2.2.1. Brachytherapy Systems 6.2.2.1.1. Electronic Brachytherapy Products 6.2.2.1.2. Afterloaders 6.3. Radiotherapy Consumables and Accessories 6.3.1. Internal Beam Radiotherapy Consumables and Accessories 6.3.1.1. Brachytherapy Consumables & Accessories 6.3.1.1.1. Brachytherapy Applicators 6.3.1.1.2. Brachytherapy Seeds 6.3.1.2. Systemic Radiation Therapy 6.3.1.2.1. Iobenguane (I-131) 6.3.1.2.2. Samarium-153 6.3.1.2.3. Rhenium-186 6.3.1.2.4. Others 6.4. Services 6.5. Software
7. Radiotherapy Market, by Technology 7.1. Introduction 7.2. External Beam Radiotherapy 7.2.1. Intensity-Modulated Radiation Therapy (IMRT) 7.2.2. Image-Guided Radiation Therapy (IGRT) 7.2.3. Stereotactic Radiation Therapy (SRT) 7.2.4. 3D Conformal Radiation Therapy (3D-CRT) 7.2.5. Particle Therapy 7.3. Internal Beam Radiotherapy 7.3.1. Brachytherapy 7.3.1.1. High-Dose Rate Brachytherapy 7.3.1.2. Low-Dose Rate Brachytherapy 7.3.1.3. Image-Guided Brachytherapy 7.3.1.4. Pulse-Dose Rate Brachytherapy 7.3.2. Systemic Radiation Therapy 7.3.2.1. Intravenous Radiotherapy 7.3.2.2. Oral Radiotherapy
8. Radiotherapy Market, by Application 8.1. Introduction 8.2. Breast Cancer 8.3. Prostate Cancer 8.4. Lung Cancer 8.5. Brain Tumour 8.6. Head and Neck Cancer 8.7. Colorectal Cancer 8.8. Cervical Cancer 8.9. Others
9. Radiotherapy Market, by End User 9.1. Introduction 9.2. Hospitals 9.3. Independent Radiotherapy Centres 9.4. Cancer Research Institutes
10. Radiotherapy Market, by Geography 10.1. Introduction 10.2. North America 10.2.1. U.S. 10.2.2. Canada 10.3. Europe 10.3.1. Germany 10.3.2. France 10.3.3. Italy 10.3.4. U.K. 10.3.5. Spain 10.3.6. Rest of Europe 10.4. Asia-Pacific 10.4.1. China 10.4.2. Japan 10.4.3. India 10.4.4. Rest of Asia-Pacific 10.5. Latin America 10.6. Middle East & Africa
11. Competitive Landscape 11.1. Competitive Growth Strategies 11.2. Competitive Benchmarking 11.3. Market Share Analysis
12. Company Profiles(Business Overview, Financial Overview, Product Portfolio, Strategic Developments) 12.1. Varian Medical Systems, Inc. 12.2. Elekta AB 12.3. Accuray Incorporated 12.4. C. R. Bard, Inc. (A Subsidiary of Becton Dickinson & Company) 12.5. Mevion Medical Systems, Inc. 12.6. Hitachi, Ltd. 12.7. ViewRay, Inc. 12.8. Panacea Medical Technologies Pvt. Ltd. 12.9. IsoRay, Inc. 12.10. Optivus Proton Therapy, Inc. 12.11. P-Cure, Ltd. 12.12. Provision Healthcare, LLC 12.13. Sumitomo Heavy Industries, Ltd. 12.14. Ion Beam Applications S.A. 12.15. Theragenics Corporation
13. Appendix 13.1. Questionnaire 13.2. Available Customization
DownloadDetailed TOC @https://www.meticulousresearch.com/request-sample-report/cp_id=5023
Related Reports:
Interventional oncology Marketby Procedure [Embolization (TARE, TACE), Ablation (Thermal Ablation (Microwave, RF Ablation))], Product [Embolization (SIR-Spheres, TheraSpheres)], Application (Liver, Lung, Breast), and End User - Global Forecast to 2025
Multimodal Imaging Marketby Product (Equipment, Reagent, Software), Technology (PET-CT, SPECT-CT, PET-MRI), Application [Clinical (Oncology, Orthopedic, Cardiology), Research], End User (Hospitals, Diagnostic Centers, Academia) - Global Forecast to 2024
Breast Imaging Marketby Technology [Ionizing (FFDM, Analog, 3D Mammogram, PEM, CT, CBCT, EIT), Non-Ionizing (Breast Ultrasound,Breast MRI, AWBU, Breast Thermography)], End User (Hospital, Diagnostic Imaging Center) - Global Forecast to 2024
Diagnostic Imaging Marketby Product (X-ray (Digital, Analog), MRI (Closed, Open), Ultrasound, CT, Nuclear Imaging (SPECT, PET), Application (Orthopedic, OB/GYN, MSK, Cardiology, Oncology), End User (Hospital, Imaging Centers) - Global Forecast to 2025
Medical Image Management MarketBy Product (PACS (Radiology, Mammography, Cardiology, Oncology, Enterprise), VNA, AICA, Universal Viewer), Delivery (On Premise, Hybrid, Cloud), End User (Hospitals, Diagnostic Imaging Center, ASC) - Global Forecast to 2024
About Meticulous Research
The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to details.
Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, with the help of its unique research methodologies, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions.
With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.
Read the original post:
Radiotherapy Market is Expected to Grow at a CAGR of 5.6% to Reach $10.15 Billion by 2025- Meticulous Research - GlobeNewswire
- Best 30 Cardiology in Secaucus, NJ with Reviews - YP.com - April 12th, 2018 [April 12th, 2018]
- Cardiology | Weill Cornell Medicine - April 14th, 2018 [April 14th, 2018]
- Cardiology Conferences 2018 | Cardiology Meetings 2018 ... - April 26th, 2018 [April 26th, 2018]
- Dr. Anil Goel, MD - Birmingham, MI - Cardiology & Clinical ... - April 26th, 2018 [April 26th, 2018]
- Clinical Physiology (Cardiology) MSc/PGDip | Middlesex ... - May 15th, 2018 [May 15th, 2018]
- Cardiology Conferences 2018 | Upcoming Cardiology ... - May 16th, 2018 [May 16th, 2018]
- Clinical Cardiology Section | Cleveland Clinic - May 27th, 2018 [May 27th, 2018]
- Journal of Clinical and Experimental Cardiology - Open ... - June 6th, 2018 [June 6th, 2018]
- Cardiology Summit 2018 | Cardiology Conferences | Heart ... - June 23rd, 2018 [June 23rd, 2018]
- Cardiology Clinical and Research Faculty Members ... - June 26th, 2018 [June 26th, 2018]
- Cardiology Conferences 2018 | Cardiology Congress 2018 ... - June 26th, 2018 [June 26th, 2018]
- About Us - New Jersey Cardiology Associates - July 8th, 2018 [July 8th, 2018]
- About Us - Ventura Clinical Trials - August 16th, 2018 [August 16th, 2018]
- Clinical Cardiology Made Ridiculously Simple: Michael A ... - August 22nd, 2018 [August 22nd, 2018]
- Clinical Cardiology - American Society of Preventive Cardiology - October 2nd, 2018 [October 2nd, 2018]
- Heart Surgery Hospital in india | Cardiology Treatment ... - October 7th, 2018 [October 7th, 2018]
- Clinical Cardiology - American Society of Preventive ... - December 3rd, 2018 [December 3rd, 2018]
- Guideline Clinical App - American College of Cardiology - December 7th, 2018 [December 7th, 2018]
- Journal of Clinical and Experimental Cardiology- Open ... - December 12th, 2018 [December 12th, 2018]
- Clinical Cardiology - Baptist Health - December 30th, 2018 [December 30th, 2018]
- Cardiology at Cancun: Topics in Clinical Cardiology - February 5th, 2019 [February 5th, 2019]
- Department of Cardiovascular Medicine, KU School of Medicine - March 10th, 2019 [March 10th, 2019]
- Towards Health Equality: Improving the Management of Cardiovascular Diseases in Women - International Atomic Energy Agency - September 21st, 2019 [September 21st, 2019]
- Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors - TCTMD - September 21st, 2019 [September 21st, 2019]
- DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF - TCTMD - September 21st, 2019 [September 21st, 2019]
- Combining Nature and Technology, Luye Medical and Cleveland Clinic Join to Build a Future Hospital in Shanghai - Yahoo Finance - September 21st, 2019 [September 21st, 2019]
- Will Renal Denervation for Hypertension Rise Again? - Medscape - September 21st, 2019 [September 21st, 2019]
- Obstructive Sleep Apnea, Sleep Symptoms, and their Association with Cardiovascular Disease - DocWire News - September 21st, 2019 [September 21st, 2019]
- CNE expands pulmonary, sleep services with Brigham & Women's physicians - Warwick Beacon - September 21st, 2019 [September 21st, 2019]
- What I Am Most Looking Forward to at TCT 2019 - TCTMD - September 21st, 2019 [September 21st, 2019]
- Serelaxin Not Linked to CV Mortality Reduction in Patients Hospitalized for Acute HF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Sacubitril-Valsartan Not Linked to Lower Hospitalization Risk, CV Death in HFpEF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- FDA clears multiuse angiography systems from Siemens Healthineers - DOTmed HealthCare Business News - September 21st, 2019 [September 21st, 2019]
- Balloon Pulmonary Angioplasty Effective for Chronic Thromboembolic PH - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- RWJBarnabas Health, St. Luke's University Health launch clinical affiliation - FierceHealthcare - September 21st, 2019 [September 21st, 2019]
- Bilirubin: A Novel Indicator of Infective Endocarditis Adverse Outcomes - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS - TCTMD - September 21st, 2019 [September 21st, 2019]
- Community-based Care Model Reduces CVD Risk - Managed Healthcare Executive - September 21st, 2019 [September 21st, 2019]
- American College of Cardiology Steps Up: Equal Pay, Opportunities for All - TCTMD - September 21st, 2019 [September 21st, 2019]
- FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form - AJMC.com Managed Markets Network - September 21st, 2019 [September 21st, 2019]
- A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred - Medscape - September 21st, 2019 [September 21st, 2019]
- Seeking Synergy: Bringing Cardiology into Your Enterprise Imaging Strategy - Health Imaging - September 21st, 2019 [September 21st, 2019]
- TCT 2019 Day Two: Transcatheter Valves, New and Old - TCTMD - September 30th, 2019 [September 30th, 2019]
- Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis - TCTMD - September 30th, 2019 [September 30th, 2019]
- Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival - Diagnostic and Interventional Cardiology - September 30th, 2019 [September 30th, 2019]
- TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3 - TCTMD - September 30th, 2019 [September 30th, 2019]
- Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy... - September 30th, 2019 [September 30th, 2019]
- Off Script: The New Gatekeepers of Procedural Education - TCTMD - September 30th, 2019 [September 30th, 2019]
- Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE - BioSpace - September 30th, 2019 [September 30th, 2019]
- The Heart of the Matter: Cardiovascular Fitness in Horses - United States Eventing Association - September 30th, 2019 [September 30th, 2019]
- Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy - FierceHealthcare - September 30th, 2019 [September 30th, 2019]
- Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy - Medscape - September 30th, 2019 [September 30th, 2019]
- New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis - Newswise - September 30th, 2019 [September 30th, 2019]
- Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Insights from the European Society of Cardiology congress | Speaking of Medicine - PLoS Blogs - September 30th, 2019 [September 30th, 2019]
- Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- AZ's Farxiga gets heart failure prevention okay from FDA - PMLiVE - October 22nd, 2019 [October 22nd, 2019]
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- The Epidemic Of The Metabolic Syndrome Among The Palestinians In The G | DMSO - Dove Medical Press - October 22nd, 2019 [October 22nd, 2019]
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis - PRNewswire - October 22nd, 2019 [October 22nd, 2019]
- Even With Same Diagnosis, Women Get Half the Heart Attack Treatments as Men - AJMC.com Managed Markets Network - October 22nd, 2019 [October 22nd, 2019]
- Eva Dickerman, Andrew Weil - The New York Times - October 22nd, 2019 [October 22nd, 2019]
- EHR vendor Veradigm and partners creating new shared data tools for researchers - Healthcare IT News - October 22nd, 2019 [October 22nd, 2019]
- Evolocumab Well-tolerated as Add-on for Hypercholesterolemia Therapy - DocWire News - October 22nd, 2019 [October 22nd, 2019]
- Deborah Heart and Lung Center announces affiliation with Cleveland Clinic Heart & Vascular Institute - Health Essentials from Cleveland Clinic - October 22nd, 2019 [October 22nd, 2019]
- New Registry to Provide Insight into STEMI Occurrence, Treatment in North India | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- Finding Your Best Fit in Cardiology - TCTMD - October 22nd, 2019 [October 22nd, 2019]
- Cardiology team expands to meet community need - The Union of Grass Valley - October 22nd, 2019 [October 22nd, 2019]
- Deaths After Ablation of Atrial Fibrillation 'Concerning' in Real-World Analysis - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cutler Family gifts $15 million to University Hospitals to transform mens health care - Newswise - November 1st, 2019 [November 1st, 2019]
- Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD - TCTMD - November 1st, 2019 [November 1st, 2019]
- Caregiving and the Soul of Medicine - Medscape - November 1st, 2019 [November 1st, 2019]
- STEMI Mortality Unaffected by Weekend, Weeknight, or Holiday Admission in France - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical publishes positive results from the AMBULATE pivotal study Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Gaps in Access to TAVR and SAVR: 'Something Needs to Be Done' - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical... - November 1st, 2019 [November 1st, 2019]
- Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential - 24/7 Wall St. - November 7th, 2019 [November 7th, 2019]
- Global Computed Tomography (CT) Scanners Devices and Equipment Market Report 2020: Major Players are GE Healthcare, Koninklijke Philips, Hitachi,... - November 7th, 2019 [November 7th, 2019]